Author: Nicole Brown
March 14 – 10 min read
What’s new, what’s next, and what it means for our business.
Published monthly, the OBX Innovation Briefing is presented by the OBX team as a way of highlighting the latest developments and innovations within the global cannabinoid industry. Each curated volume features insights and commentary on industry and category trends, regulatory updates, key initiatives, and upcoming events.
BRAND NEWS
Cresco Labs to Buy Columbia Care in $2 Billion Cannabis Deal
- Cresco Labs Inc. plans to buy Columbia Care Inc. for about $2 billion in one of the largest cannabis industry mergers yet.
- The deal will combine Cresco’s well-recognized marijuana brands with New York-based Columbia Care’s retail footprint to create the largest U.S. multi-state operator by revenue, Cresco Chief Executive Officer Charlie Bachtell said in an interview.
- Bachtell, who will lead the combined company, said the transaction will expand Cresco’s presence to 17 states, plus the District of Columbia, up from 10 states.
- It will also give Chicago-based Cresco the top market share in Illinois, Pennsylvania, Colorado and Virginia.
- “This is how you turn brands like High Life, Cresco and FloraCal into Miller High Life, Coca-Cola and Johnnie Walker Blue Label,” Bachtell said.
Equilibria Acquires Fleur Marché: ‘CBD Is Just The Beginning’
- CBD brand Fleur Marché has been acquired by functional wellness and CBD company Equilibria for an undisclosed amount.
- As part of the deal announced on Tuesday, Fleur Marché and its team will continue to operate independently, with co-founders Ashley Lewis and Meredith Schroeder remaining at the helm. Following the acquisition, Equilibria will support Fleur Marché in areas including product development, innovation and national distribution.
- Equilibria was also launched in 2019 and has raised a total of $5 million led by cannabis fund Salveo Capital and Hyde Park Angels, with participation from the venture arm of an unnamed global CPG conglomerate. It sells its brand of CBD ingestibles and topicals exclusively via its DTC site and defines itself as part of the “telehealth” arena, said Meers.
- The brands are also focused on different age demographics. While Equilibria’s main customer demographic is postmenopausal women, Fleur Marché is targeting Gen Z.
- The goal for the next phase in growth after the acquisition will be “focused on helping Fleur Marché achieve massive scale” in national retail.
SōRSE Technology Enters Thailand’s CBD Marketplace via Exclusive Partnership with Hempagoda
- SōRSE Technology’s water-soluble emulsions for Consumer Packaged Goods available in Thailand through Hempagoda.
- SōRSE will be the first US water-soluble cannabinoid and hemp emulsion technology available in Thailand.
- The SōRSE/Hempogoda partnership creates exciting opportunities for Thai producers to develop unique, high quality and great-tasting products Powered by SōRSE.
- Brands currently Powered by SōRSE can also distribute their products in Thailand in partnership with Hempagoda.
Cann Debuts New Variety With and Without THC
- Cann has launched a limited-edition flavor, Blue Rhuberry, in partnership with investor and comedic actor Adam Devine and Eaze, the nation’s largest cannabis delivery marketplace.
- Featuring rhubarb, raspberry, blue butterfly pea tea and a microdose of THC, this limited-edition flavor comes in a 4-pack of hi boys (5 mg THC) and is available exclusively through Eaze in California.
- For the first time, Cann is launching this collaboration flavor in a “dry boy” Unspiked format nationwide, offering consumers the same delicious flavor of Cann without the THC.
Labatt Shutters CBD Beverage Unit In Canada
- Labatt Breweries of Canada, one of the country’s top beer makers, pulled the plug on its nonalcoholic CBD beverage unit in Canada, Fluent Beverages, signaling continued pressure on Canada’s fledgling infused-drinks category.
- Fluent had been born from a partnership between Budweiser maker AB InBev, the world’s largest brewer, and cannabis producer Tilray.
- But that relationship ended three months ago, leaving the cannabis beverage maker solely in the hands of Labatt. Labatt is a subsidiary of AB InBev.
- At the time, Labatt said it intended to operate the unit as a wholly owned subsidiary and its day-to-day operations were focused on commercializing CBD-infused beverages.
- Flora’s JustCBD brand will launch sales of its premium CBD products in airports across the US, distributed by distribution company OTG Management.
- Initial airports to distribute JustCBD include Houston’s George Bush Intercontinental/Houston Airport (IAH) and Washington, DC’s Ronald Reagan Washington National Airport (DCA).
- JustCBD’s night-time gummies and its regular JustCBD gummies are the first SKUs ordered by OTG Management.
Demetrix and Evonik Sign Supply Agreement For Cannabinoids
- Demetrix and German global specialty chemicals company Evonik, announce a supply agreement for cannabinoids to be used in beauty and personal care products. The first product, CBG (cannabigerol) will be entering the market in 2022.
- Coupling Demetrix’s proven production technology and Evonik’s leadership position as a sustainable specialties partner to the top beauty and personal care brands, this multi-year relationship focuses on bringing cannabinoids to global markets.
- “Evonik is a global leader in supplying innovative solutions to the beauty and personal care markets in more than 100 countries,” says Cynthia Bryant, Demetrix CBO. “This partnership speaks to the growing demand for high purity cannabinoids because of the benefits they can provide for consumers.”
Trend Pieces And Editorials
In These Tense Times, CBD Is Thriving
The growing use of CBD is a telling indicator of consumer mindsets in 2022. In these tense times, consumers are in search of products that can facilitate their mental health goals. Even food & beverage brands that aren’t interested in including CBD in their portfolios can pursue these benefits through alternative products.
1 in 3 U.S. adults, and half of millennials, have tried a CBD product
- Before the pandemic, CBD went from a secret compound enjoyed by elites to a nearly unavoidable presence in retail stores across the country. Part of the chemical’s appeal lies in its universal applications: infused sparkling waters, chocolates, bath bombs and, of course, gummies.
- CBD’s ubiquity has led to an increase in awareness among U.S. adults, rising 5 percentage points since June 2019 to 65 percent. Usage, meanwhile, increased from around 1 in 4 to 1 in 3 over that same time period, with the share of respondents who have tried CBD products rising across every generation.
- Perceptions of legality may play a role in the increasing usage: 73 percent of consumers now say CBD is legal, versus 61 percent in 2019. But a larger factor is likely the pandemic. This usage increase coincides with a period of heightened stress and anxiety stemming from both the pandemic and its economic toll. Amid the ongoing health crisis, consumers are looking for healthy methods to manage their physical, emotional and mental well-being.
Pain relief is seen as CBD’s top benefit, but mental health advantages enhance appeal for millennials
- The health benefit most associated with CBD is pain relief. But millennials — the generation credited with normalizing discourse about mental health — are especially attracted to CBD for its mental wellness benefits, including reducing anxiety, improving sleep and offsetting symptoms of depression, which nearly half believe it can help with.
- The pandemic has put mental health in the spotlight: 61 percent of millennials and 52 percent of U.S. adults said in January 2022 that “anxious” described their mood well, while a roughly equal share of U.S. adults said the same in January 2021. With Gen Z taking up the mantle in continuing mental health conversations, CBD (and likely THC) usage should continue to grow.
Cannabis Winemaker Jamie Evans on the Future of Hybrid Beverages
- Infused drinks are one of the fastest growing cannabis categories and poised to become one of the largest categories in the edible space. There is a lot of money coming from traditional beverage companies and an enormous potential for growth. In the past three to four years, there’s been so much innovation going into this space and now there are professional products that are shelf stable.
- It’s becoming mainstream—there are a lot of celebrities coming out with cannabis beverages, as well as athletes. It started with seltzers and tonics, but now that we have the ability to create cannabis-infused aperitifs, dealcoholized beer, cider and wine, the possibility is immense.
- The future’s very bright; there’s a lot of momentum and excitement. We can produce these beautiful, shelf-stable products that taste great. There are only a handful of cannabis-infused wine producers that are infusing with THC, so there is an exciting opportunity there. As the low- and no-alcohol categories grow, it helps the cannabis drink messaging. These beverages deliver a buzz, and you might still want a buzz but don’t want the side effects of alcohol. One day, I would love to see cannabis-infused wine bars. It’s only a matter of time before we see on-premise, consumer-facing experiences.
Why CBD & Retinol Are The “Most Impressive” Ingredient Combo In Skin Care
- The study’s results and key findings proved so impressive that they were published in the most recent issue of the Aesthetic Surgery Journal. “What we found is that the results went even further than my hypothesis,” Dr. Few explains. “Not only was the retinol working with no irritation, because of the CBD, but the combination of the two led to decreased inflammation in the skin.”
- The combined use of water-soluble CBD and retinol proved to treat a wide range of common skin concerns, including acne and rosacea. “Participants with acne, both male and female, saw results,” Dr. Few explains. “I had someone with pretty significant maskne, especially around her menstrual cycle, and after two weeks of use, it was gone. Not just reduced, gone. Even patients with rosacea, who often struggle with retinol because it can make rosacea symptoms worse, they saw skin improvement with the combination of CBD and retinol.”
Regulatory
House Passes MORE Act to Federally Legalize Cannabis
- The U.S. House approved the MORE Act today – a federal cannabis legalization bill introduced by New York Rep. Jerrold Nadler (D) – in a bipartisan 220-204 vote.
- The measure seeks to remove cannabis from the federal Controlled Substances Act, impose a federal tax on cannabis product sales, and establish an expungement process for prior cannabis convictions. The House previously passed the measure in December 2020 but it was not brought to the Senate floor for a vote, which was controlled by Republicans at the time.
- It’s unclear whether the measure has enough support to clear a filibuster in the Senate – which requires 60 votes – and Democratic Senators Joe Manchin (W. Va) and Jeanne Shaheen (NH) have both expressed skepticism about legalizing cannabis federally, according to The Hill.
Everything You Need To Know About The FSA’s CBD List
- For CBD producers, the list that the Food Standards Agency (FSA) has now collated is an essential stepping stone to becoming authorized in England and Wales.
- The FSA is recommending to local authorities that the products on the list marked as ‘Validated’ or ‘Awaiting evidence’ may stay on the market in England and Wales, pending further consideration. It is important to note that validation is not the same as authorisation and there’s no guarantee that a validated application will be authorized.
- Products on the list have been undergoing assessment by the FSA, which was open to any CBD product designed for oral consumption on sale on or before 13 February 2020. Products that were launched after this date are not permitted for sale until they are granted full authorisation.
- It is worth noting that products designed to be inhaled, such as vapes, or applied to the skin, including cosmetics and massage oils, do not fall under the FSA’s remit. These were not assessed and will not appear on the list.
- Businesses selling CBD products – including supermarkets, convenience stores, health food shops, pharmacies, online retailers, cafés and restaurants – will need to check their current stock against the list to ensure they’re compliant. To help with this, ACI has created a new website.
Category & Research Trends
Canopy Growth Shines A Light On Menstrual Health Through CBD Efficacy Study
- Nearly 75% of reproductive-aged menstruating individuals report experiencing unpleasant menstrual-related symptoms, ranging from cramping and bloating to back pain and shifts in mood including irritability and stress. This study marks the first exploration of the effects of cannabinoids for symptom management.
- Over the course of six months, 40 participants who experienced moderate to severe menstrual-related symptoms were randomized to receive 160mg or 320mg of CBD, in divided doses twice daily for 5 days each month beginning the first day they experienced symptoms.
- Results showed significantly reduced menstrual-related symptoms over the 6 months relative to a one-month baseline, and the higher dose was also effective in significantly reducing irritability and stress over the same period. The data collected from this study is the first of its kind to demonstrate the efficacy of cannabis-based therapies to treat symptoms experienced by individuals, including those related to menstruation.
Open Book Extracts Announces Completion of Study on Rare Cannabinoids for Pain
- Open Book Extracts (OBX), a cGMP-certified manufacturer and distributor of cannabinoid ingredients, announced the completion of its first randomized, controlled trial on rare cannabinoids to evaluate the effect they have on longer-term pain, well-being, and quality of life. The study is being conducted with the support of Radicle Science, a health technology B-corp focused on validating health and wellness products for the first time.
- Radicle conducted a study on several OBX formulations, which ran for four weeks and was of a blinded, randomized, placebo-controlled, parallel group.
- The results of the study will be announced upon their return, which is expected by late April of this year.
Upcoming Events & Webinars
- Supply Side East (April 12 & 13, Secaucus, NJ)
- Benzinga Cannabis Capital Conference (April 20 & 21, Miami, FL)
- Luxury Meets Cannabis (May 5 & 6, NYC)
- Trailblazers (May 10 – 12, Sedona, AZ)
- MJ Unpacked (May 18 – 20, NYC)
Got Innovation? If you see an interesting new brand, trend or other innovative idea, please feel free to share directly to nicole@openbookextracts, or you can share in the #innovation Slack channel. All ideas are welcome!
Author: Nicole Brown
March 14 – 10 min read
What’s new, what’s next, and what it means for our business.
Published monthly, the OBX Innovation Briefing is presented by the OBX team as a way of highlighting the latest developments and innovations within the global cannabinoid industry. Each curated volume features insights and commentary on industry and category trends, regulatory updates, key initiatives, and upcoming events.
BRAND NEWS
Cresco Labs to Buy Columbia Care in $2 Billion Cannabis Deal
- Cresco Labs Inc. plans to buy Columbia Care Inc. for about $2 billion in one of the largest cannabis industry mergers yet.
- The deal will combine Cresco’s well-recognized marijuana brands with New York-based Columbia Care’s retail footprint to create the largest U.S. multi-state operator by revenue, Cresco Chief Executive Officer Charlie Bachtell said in an interview.
- Bachtell, who will lead the combined company, said the transaction will expand Cresco’s presence to 17 states, plus the District of Columbia, up from 10 states.
- It will also give Chicago-based Cresco the top market share in Illinois, Pennsylvania, Colorado and Virginia.
- “This is how you turn brands like High Life, Cresco and FloraCal into Miller High Life, Coca-Cola and Johnnie Walker Blue Label,” Bachtell said.
Equilibria Acquires Fleur Marché: ‘CBD Is Just The Beginning’
- CBD brand Fleur Marché has been acquired by functional wellness and CBD company Equilibria for an undisclosed amount.
- As part of the deal announced on Tuesday, Fleur Marché and its team will continue to operate independently, with co-founders Ashley Lewis and Meredith Schroeder remaining at the helm. Following the acquisition, Equilibria will support Fleur Marché in areas including product development, innovation and national distribution.
- Equilibria was also launched in 2019 and has raised a total of $5 million led by cannabis fund Salveo Capital and Hyde Park Angels, with participation from the venture arm of an unnamed global CPG conglomerate. It sells its brand of CBD ingestibles and topicals exclusively via its DTC site and defines itself as part of the “telehealth” arena, said Meers.
- The brands are also focused on different age demographics. While Equilibria’s main customer demographic is postmenopausal women, Fleur Marché is targeting Gen Z.
- The goal for the next phase in growth after the acquisition will be “focused on helping Fleur Marché achieve massive scale” in national retail.
SōRSE Technology Enters Thailand’s CBD Marketplace via Exclusive Partnership with Hempagoda
- SōRSE Technology’s water-soluble emulsions for Consumer Packaged Goods available in Thailand through Hempagoda.
- SōRSE will be the first US water-soluble cannabinoid and hemp emulsion technology available in Thailand.
- The SōRSE/Hempogoda partnership creates exciting opportunities for Thai producers to develop unique, high quality and great-tasting products Powered by SōRSE.
- Brands currently Powered by SōRSE can also distribute their products in Thailand in partnership with Hempagoda.
Cann Debuts New Variety With and Without THC
- Cann has launched a limited-edition flavor, Blue Rhuberry, in partnership with investor and comedic actor Adam Devine and Eaze, the nation’s largest cannabis delivery marketplace.
- Featuring rhubarb, raspberry, blue butterfly pea tea and a microdose of THC, this limited-edition flavor comes in a 4-pack of hi boys (5 mg THC) and is available exclusively through Eaze in California.
- For the first time, Cann is launching this collaboration flavor in a “dry boy” Unspiked format nationwide, offering consumers the same delicious flavor of Cann without the THC.
Labatt Shutters CBD Beverage Unit In Canada
- Labatt Breweries of Canada, one of the country’s top beer makers, pulled the plug on its nonalcoholic CBD beverage unit in Canada, Fluent Beverages, signaling continued pressure on Canada’s fledgling infused-drinks category.
- Fluent had been born from a partnership between Budweiser maker AB InBev, the world’s largest brewer, and cannabis producer Tilray.
- But that relationship ended three months ago, leaving the cannabis beverage maker solely in the hands of Labatt. Labatt is a subsidiary of AB InBev.
- At the time, Labatt said it intended to operate the unit as a wholly owned subsidiary and its day-to-day operations were focused on commercializing CBD-infused beverages.
- Flora’s JustCBD brand will launch sales of its premium CBD products in airports across the US, distributed by distribution company OTG Management.
- Initial airports to distribute JustCBD include Houston’s George Bush Intercontinental/Houston Airport (IAH) and Washington, DC’s Ronald Reagan Washington National Airport (DCA).
- JustCBD’s night-time gummies and its regular JustCBD gummies are the first SKUs ordered by OTG Management.
Demetrix and Evonik Sign Supply Agreement For Cannabinoids
- Demetrix and German global specialty chemicals company Evonik, announce a supply agreement for cannabinoids to be used in beauty and personal care products. The first product, CBG (cannabigerol) will be entering the market in 2022.
- Coupling Demetrix’s proven production technology and Evonik’s leadership position as a sustainable specialties partner to the top beauty and personal care brands, this multi-year relationship focuses on bringing cannabinoids to global markets.
- “Evonik is a global leader in supplying innovative solutions to the beauty and personal care markets in more than 100 countries,” says Cynthia Bryant, Demetrix CBO. “This partnership speaks to the growing demand for high purity cannabinoids because of the benefits they can provide for consumers.”
Trend Pieces And Editorials
In These Tense Times, CBD Is Thriving
The growing use of CBD is a telling indicator of consumer mindsets in 2022. In these tense times, consumers are in search of products that can facilitate their mental health goals. Even food & beverage brands that aren’t interested in including CBD in their portfolios can pursue these benefits through alternative products.
1 in 3 U.S. adults, and half of millennials, have tried a CBD product
- Before the pandemic, CBD went from a secret compound enjoyed by elites to a nearly unavoidable presence in retail stores across the country. Part of the chemical’s appeal lies in its universal applications: infused sparkling waters, chocolates, bath bombs and, of course, gummies.
- CBD’s ubiquity has led to an increase in awareness among U.S. adults, rising 5 percentage points since June 2019 to 65 percent. Usage, meanwhile, increased from around 1 in 4 to 1 in 3 over that same time period, with the share of respondents who have tried CBD products rising across every generation.
- Perceptions of legality may play a role in the increasing usage: 73 percent of consumers now say CBD is legal, versus 61 percent in 2019. But a larger factor is likely the pandemic. This usage increase coincides with a period of heightened stress and anxiety stemming from both the pandemic and its economic toll. Amid the ongoing health crisis, consumers are looking for healthy methods to manage their physical, emotional and mental well-being.
Pain relief is seen as CBD’s top benefit, but mental health advantages enhance appeal for millennials
- The health benefit most associated with CBD is pain relief. But millennials — the generation credited with normalizing discourse about mental health — are especially attracted to CBD for its mental wellness benefits, including reducing anxiety, improving sleep and offsetting symptoms of depression, which nearly half believe it can help with.
- The pandemic has put mental health in the spotlight: 61 percent of millennials and 52 percent of U.S. adults said in January 2022 that “anxious” described their mood well, while a roughly equal share of U.S. adults said the same in January 2021. With Gen Z taking up the mantle in continuing mental health conversations, CBD (and likely THC) usage should continue to grow.
Cannabis Winemaker Jamie Evans on the Future of Hybrid Beverages
- Infused drinks are one of the fastest growing cannabis categories and poised to become one of the largest categories in the edible space. There is a lot of money coming from traditional beverage companies and an enormous potential for growth. In the past three to four years, there’s been so much innovation going into this space and now there are professional products that are shelf stable.
- It’s becoming mainstream—there are a lot of celebrities coming out with cannabis beverages, as well as athletes. It started with seltzers and tonics, but now that we have the ability to create cannabis-infused aperitifs, dealcoholized beer, cider and wine, the possibility is immense.
- The future’s very bright; there’s a lot of momentum and excitement. We can produce these beautiful, shelf-stable products that taste great. There are only a handful of cannabis-infused wine producers that are infusing with THC, so there is an exciting opportunity there. As the low- and no-alcohol categories grow, it helps the cannabis drink messaging. These beverages deliver a buzz, and you might still want a buzz but don’t want the side effects of alcohol. One day, I would love to see cannabis-infused wine bars. It’s only a matter of time before we see on-premise, consumer-facing experiences.
Why CBD & Retinol Are The “Most Impressive” Ingredient Combo In Skin Care
- The study’s results and key findings proved so impressive that they were published in the most recent issue of the Aesthetic Surgery Journal. “What we found is that the results went even further than my hypothesis,” Dr. Few explains. “Not only was the retinol working with no irritation, because of the CBD, but the combination of the two led to decreased inflammation in the skin.”
- The combined use of water-soluble CBD and retinol proved to treat a wide range of common skin concerns, including acne and rosacea. “Participants with acne, both male and female, saw results,” Dr. Few explains. “I had someone with pretty significant maskne, especially around her menstrual cycle, and after two weeks of use, it was gone. Not just reduced, gone. Even patients with rosacea, who often struggle with retinol because it can make rosacea symptoms worse, they saw skin improvement with the combination of CBD and retinol.”
Regulatory
House Passes MORE Act to Federally Legalize Cannabis
- The U.S. House approved the MORE Act today – a federal cannabis legalization bill introduced by New York Rep. Jerrold Nadler (D) – in a bipartisan 220-204 vote.
- The measure seeks to remove cannabis from the federal Controlled Substances Act, impose a federal tax on cannabis product sales, and establish an expungement process for prior cannabis convictions. The House previously passed the measure in December 2020 but it was not brought to the Senate floor for a vote, which was controlled by Republicans at the time.
- It’s unclear whether the measure has enough support to clear a filibuster in the Senate – which requires 60 votes – and Democratic Senators Joe Manchin (W. Va) and Jeanne Shaheen (NH) have both expressed skepticism about legalizing cannabis federally, according to The Hill.
Everything You Need To Know About The FSA’s CBD List
- For CBD producers, the list that the Food Standards Agency (FSA) has now collated is an essential stepping stone to becoming authorized in England and Wales.
- The FSA is recommending to local authorities that the products on the list marked as ‘Validated’ or ‘Awaiting evidence’ may stay on the market in England and Wales, pending further consideration. It is important to note that validation is not the same as authorisation and there’s no guarantee that a validated application will be authorized.
- Products on the list have been undergoing assessment by the FSA, which was open to any CBD product designed for oral consumption on sale on or before 13 February 2020. Products that were launched after this date are not permitted for sale until they are granted full authorisation.
- It is worth noting that products designed to be inhaled, such as vapes, or applied to the skin, including cosmetics and massage oils, do not fall under the FSA’s remit. These were not assessed and will not appear on the list.
- Businesses selling CBD products – including supermarkets, convenience stores, health food shops, pharmacies, online retailers, cafés and restaurants – will need to check their current stock against the list to ensure they’re compliant. To help with this, ACI has created a new website.
Category & Research Trends
Canopy Growth Shines A Light On Menstrual Health Through CBD Efficacy Study
- Nearly 75% of reproductive-aged menstruating individuals report experiencing unpleasant menstrual-related symptoms, ranging from cramping and bloating to back pain and shifts in mood including irritability and stress. This study marks the first exploration of the effects of cannabinoids for symptom management.
- Over the course of six months, 40 participants who experienced moderate to severe menstrual-related symptoms were randomized to receive 160mg or 320mg of CBD, in divided doses twice daily for 5 days each month beginning the first day they experienced symptoms.
- Results showed significantly reduced menstrual-related symptoms over the 6 months relative to a one-month baseline, and the higher dose was also effective in significantly reducing irritability and stress over the same period. The data collected from this study is the first of its kind to demonstrate the efficacy of cannabis-based therapies to treat symptoms experienced by individuals, including those related to menstruation.
Open Book Extracts Announces Completion of Study on Rare Cannabinoids for Pain
- Open Book Extracts (OBX), a cGMP-certified manufacturer and distributor of cannabinoid ingredients, announced the completion of its first randomized, controlled trial on rare cannabinoids to evaluate the effect they have on longer-term pain, well-being, and quality of life. The study is being conducted with the support of Radicle Science, a health technology B-corp focused on validating health and wellness products for the first time.
- Radicle conducted a study on several OBX formulations, which ran for four weeks and was of a blinded, randomized, placebo-controlled, parallel group.
- The results of the study will be announced upon their return, which is expected by late April of this year.
Upcoming Events & Webinars
- Supply Side East (April 12 & 13, Secaucus, NJ)
- Benzinga Cannabis Capital Conference (April 20 & 21, Miami, FL)
- Luxury Meets Cannabis (May 5 & 6, NYC)
- Trailblazers (May 10 – 12, Sedona, AZ)
- MJ Unpacked (May 18 – 20, NYC)
Got Innovation? If you see an interesting new brand, trend or other innovative idea, please feel free to share directly to nicole@openbookextracts, or you can share in the #innovation Slack channel. All ideas are welcome!
